Alentis Therapeutics

Alentis Therapeutics is a clinical-stage biotech company dedicated to developing groundbreaking treatments for Claudin-1 positive (CLDN1+) tumors and organ fibrosis. Their mission is to treat cancer and reverse fibrosis by targeting the CLDN1 protein, a previously unexploited target that plays a key role in the pathology of both conditions. They are rapidly advancing a pipeline of first-in-class monoclonal antibodies (mAbs) and antibody-drug conjugates (ADCs) that specifically bind exposed CLDN1 in tumors and fibrotic tissue.

Alentis was founded in 2019 based on groundbreaking research by Professor Thomas Baumert at the University of Strasbourg and the French National Institute of Health and Medical Research (Inserm). They are headquartered in Basel, Switzerland, with an R&D subsidiary in Strasbourg, France, and clinical operations in the US. Their team is committed to unlocking the broad potential of their therapeutic target, CLDN1, and bringing new treatments to those in need.

Alentis Therapeutics does not explicitly state their job flexibility policies on their website. NONE

Alentis Therapeutics is a clinical-stage biotechnology company focused on developing innovative treatments for Claudin-1 positive (CLDN1+) tumors and organ fibrosis. Their mission is to treat cancer and reverse fibrosis by harnessing the therapeutic potential of Claudin-1, a previously unexplored target that plays a critical role in the pathology of both diseases. The company is rapidly advancing a pipeline of first-in-class monoclonal antibodies (mAbs) and antibody-drug conjugates (ADCs) that specifically target exposed CLDN1, aiming to address the unmet medical needs of patients suffering from these debilitating conditions.

Alentis Therapeutics fosters a collaborative and supportive culture that prioritizes hard work and a shared belief in the transformative potential of their anti-Claudin-1 therapies. The company values a fast-paced environment where trust and quick decision-making are encouraged, allowing them to achieve ambitious goals and make a difference for patients.

Alentis Therapeutics prioritizes a culture of collaboration and hard work, valuing a diverse team that shares the belief that anti-Claudin-1 therapies will benefit patients. While the company does not explicitly state its approach to diversity, equity, and inclusion, its emphasis on attracting talent from across the healthcare, life science, pharmaceutical, and biotechnology sectors implies a commitment to building a diverse team. The company's efforts to attract talent and build a supportive environment suggest a focus on creating an inclusive workplace where all team members feel valued and respected.